Longitudinal Assessment of Imatinib’s Effect on the Blood–Brain Barrier After Ischemia/Reperfusion Injury with Permeability MRI

Abstract

Acute ischemic stroke (AIS) often results in degeneration of the blood-brain barrier (BBB), which can lead to vasogenic edema and an increased risk of intracerebral hemorrhage. Imatinib is an agent that may be able to protect the BBB and reduce the risk of the harmful consequences of BBB degeneration. We sought to measure the effect of Imatinib on the BBB after experimental stroke longitudinally in vivo with permeability dynamic contrast-enhanced MRI. Ischemia/reperfusion injury was induced with a transient middle cerebral artery occlusion surgery. Rats were given Imatinib at 2 and 20 h after stroke onset. Post-assessment included neurologic functioning, MR imaging, Evans Blue extravasation, Western blot, and immunohistology assay. Imatinib protected the BBB by 24 h but failed to decrease BBB permeability at an earlier time-point. Imatinib also reduced infarct volume, edema, and improved neurologic functioning by 24 h. Rats treated with Imatinib also had a higher expression of the BBB structural protein Zona ocludens-1 and a reduction in nuclear factor-kappa beta (NF-κβ) activation. Imatinib is a promising agent to protect the BBB after AIS, but its effect on the BBB may not become prominent until 24 h after the onset of ischemia. This finding may help elucidate Imatinib's role in the clinical management of AIS and influence future study designs.

Predictors for Cerebral Edema in Acute Ischemic Stroke Treated With Intravenous Thrombolysis

“…10 Furthermore, animal studies and a pilot clinical study indicate that drugs that maintain the integrity of BBB may improve clinical outcome after acute ischemic stroke in tPA treated patients. 18,34,35 In our study, CED was associated with all types of SICH. Our data do not allow conclusions about the risk of CED in IVT patients versus non-IVT patients.…”

Rat models of spinal cord injury: from pathology to potential therapies

“…With respect to the acute release of cytokines in the cerebrospinal fluid, rats and humans respond similarly; however, the cytokine release profile in humans is extended over time relative to that in the rat (Kwon et al, 2010). To date, the cancer drug imatinib has been shown to be protective in several rodent studies of CNS injuries and disorders (Adzemovic et al, 2013; Merali et al, 2015; Su et al, 2015; Ma et al, 2011; Abrams et al, 2012), and a first report from a Phase 2 clinical trial with imatinib after stroke suggests that imatinib might be clinically effective ().…”

Progress of Research on Diffuse Axonal Injury after Traumatic Brain Injury

“…Most axons show signs of calpain-mediated hydrolysis of spectrin 1-2 h after the injury. Related pathological changes include loss of microtubules, swelling of the mitochondria, and neurofilamentous knots, which indicate that calpain-mediated hydrolysis of structural protein and degradation of the cytoskeleton play important roles in the development and progression of DAI pathology [11–13]. …”